Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital
Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.
Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.
Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.
Jan Willem Popma
Director, Ace Pharmaceuticals BV
Talk to the deal team
Permali Gloucester has been acquired by Diamorph (subject to regulatory approval)
Private equity firm 3i Group and the private shareholders of Permali Gloucester Limited have sold their interest in the company to Diamorph.Learn more
Kirkenes Fondsforvaltning has sold a minority stake in Baltic Pork to Mork Engebretsen Invest
Kirkenes Fondsforvaltning, a Norwegian state-backed CEE investment fund, has sold a minority stake in Baltic Pork LLC, one of the largest Latvian pig farming businesses, to Mork Engebretsen Invest, a Norwegian private investor.Learn more
BaltCap has sold Labochema to French laboratory supply distributor Dominique Dutscher
BaltCap Lithuania SME Fund has sold its 46% shareholding in Labochema UAB, a Lithuanian laboratory supplies trading company, to Dominique Dutscher. Labochema’s CEO and the chairman also sold their shareholdings. As a result of the transaction, Dominique Dutscher now controls 100% of Labochema.Learn more